News Quantified

EXEL – exelixis, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Assessing Exelixis (EXEL) Valuation After Recent Short Term Share Price Pressure [Yahoo! Finance]

Exelixis: The Double Backbone Potential Of CABOMETYX And Zanzalintinib [Seeking Alpha]

Exelixis: Stable Demand And High Margins With Undervalued Shares [Seeking Alpha]

RBC Capital Lowers Exelixis (EXEL) Price Target to $43 [Yahoo! Finance]

Exelixis (EXEL) was upgraded by Truist Financial Corporation to "strong-buy".

-0.6%

BEAT

6.5%

BEAT

-14.2%

BEAT

20.8%

BEAT

Form DEFA14A EXELIXIS, INC.

Form DEFA14A EXELIXIS, INC.

Form DEF 14A EXELIXIS, INC. For: May 26

Form SCHEDULE 13G/A EXELIXIS, INC. Filed by: VANGUARD GROUP INC

Form 4 EXELIXIS, INC. For: Feb 26 Filed by: Aftab Dana

Top News Gainers

4/17 Form 4 EXELIXIS, INC. For: Apr 15 Filed by: SCANGOS GEORGE A 21.5%

6/20 Exelixis lower after IMspire170 fails to meet primary endpoint [Seeking Alpha] 9.0%

4/22 Form 4 EXELIXIS, INC. For: Apr 20 Filed by: Haley Patrick J. 7.6%

4/3 Form 4 EXELIXIS, INC. For: Apr 03 Filed by: WYSZOMIERSKI JACK L 6.7%

1/13 Form 8-K EXELIXIS, INC. For: Jan 12 6.6%

1/7 Exelixis, Inc. (NASDAQ: EXEL) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 6.1%

7/15 Exelixis Updates Phase 1b COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Patients With Advanced Solid Tumors 6.0%

11/13 Exelixis, Inc. (NASDAQ: EXEL) is now covered by analysts at Bank of America Corp. They set a "buy" rating on the stock. 6.0%

4/21 Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at Barclays PLC. They now have a $30.00 price target on the stock. 5.6%

1/13 Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at Bank of America Corp. They now have a $21.00 price target on the stock, down previously from $22.00. 4.9%

Top News Decliners

10/30 Exelixis Announces Third Quarter 2019 Financial Results and Provides Corporate Update -14.9%

3/13 Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at William Blair. -13.8%

1/24 Exelixis up 1% premarket on Cabometyx data in liver cancer [Seeking Alpha] -8.7%

7/31 Form 8-K EXELIXIS, INC. For: Jul 31 -6.5%

10/3 Form 4 EXELIXIS, INC. For: Oct 01 Filed by: Schwab Gisela -6.3%

4/9 Form DEF 14A EXELIXIS, INC. For: May 20 -5.2%

4/29 Form 4 EXELIXIS, INC. For: Apr 27 Filed by: MORRISSEY MICHAEL -5.0%

12/5 How Should Investors React To Exelixis, Inc.'s (NASDAQ:EXEL) CEO Pay? [Yahoo! Finance News] -4.6%

3/10 Exelixis, Inc. (EXEL) CEO Mike Morrissey Presents at Barclays Global Healthcare Conference 2020 (Transcript) [Seeking Alpha] -4.6%

12/6 Hedge Funds Are Warming Up To Exelixis, Inc. (EXEL) [Yahoo! Finance News] -4.5%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day